Posts by Corina

has Announced Emergency Use Authorization of Aviptadil in Nation

Relief Reports that its U.S. Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia

Geneva, Switzerland, July 28, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“Relief”), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its collaboration partner, NRx Pharmaceuticals, Inc., (Nasdaq: NRXP) (“NRx”) reported in a press release yesterday that the Nation of Georgia's Prime Minister and Minister of Health have issued an Emergency Use Authorization for intravenous aviptadil for the treatment of critical COVID-19.

NRx also reported that the first doses of aviptadil will arrive in the Nation of Georgia within 24 hours, and discussions are underway with the Ministry of Health to provide access to ZYESAMI™ to Georgians suffering with Critical COVID-19.

https://finance.yahoo.com/quote/RLFTF/community?p=RLFTF

Dear Mr. Hooter:

Thank you for your inquiry.

Relief owns U.S. Patent No. 8,178,489, related Patents derived from U.S. Patent Application Serial No. 11/817,867 and foreign formulation patents, which are being utilized under the Collaboration agreement with NeuroRx. Under the collaboration agreement, all potential new IP obtained by either Relief or NeuroRx related to aviptadil is required to be cross-licensed between the parties.

The binding collaboration agreement between Relief Therapeutics and NeuroRx entered into in September 2020 remains in full force and effect. Relief believes that it is in compliance with the collaboration agreement and that there are no grounds for renegotiating the profit sharing arrangements contained in the collaboration agreement. According to the agreement, Relief is entitled to 50% of the net profits from the sales in the NeuroRx territory, which includes the U.S., Canada and Israel.

Regarding questions relating to Relief's funding of the U.S. COVID-19 inhaled trial being conducted by NeuroRx, Relief has always been willing and able to fund the inhaled trial, upon NeuroRx presenting a detailed budget containing appropriate line items and underlying amounts and upon NeuroRx answering reasonable questions that we have posed to them asking for more details about their proposed trial budget. This has not happened to date. Nevertheless, we would also like to point out that Relief has already funded substantial expenses associated with NeuroRx's U.S. inhaled trial.

Kind regards,
Relief Therapeutics

has acquired controlling shareholding in SynchroNet

SoftwareONE Holding AG, a leading global provider of end-to-end software and cloud technology solutions, today announced that it has acquired a controlling shareholding in SynchroNet, an AWS-focused cloud specialist in digital workplace solutions. The acquisition expands SoftwareONE's capabilities in the fast-growing market of cloud-based services for remote working and complements its global AWS services portfolio.

Relief also today provided an update on development plans for RL

Intravenous (IV) formulation: Relief is currently preparing a European phase 2b/3 study with IV RLF-100 in COVID-19 patients. Once an Emergency Use Authorization (“EUA”) application is submitted by partner, NeuroRx, Inc., to the U.S. Food and Drug Administration (“FDA”) and a decision is made, Relief will determine the best path forward for the development of IV RLF-100 in Europe and other territories. Relief continues to see the potential value of RLF-100 to help patients with COVID-19-induced lung injury and hopes that, should the FDA grant EUA for RLF-100, this could expedite the clinical assessment of RLF-100 in Europe.

Clinical development of IV RLF-100 in non-COVID-19-induced ARDS is also under consideration.

Inhaled formulation: Relief will decide on additional clinical development pathways for inhaled RLF-100 in patients with moderate to severe COVID-19-induced lung injury, leveraging the learnings from the study by Prof. Leuppi.

Relief also plans to initiate a phase 2 dose-finding study with inhaled RLF-100 in pulmonary sarcoidosis in Europe in the second half of 2021.

Additional indications such as Beryllium Disease and checkpoint inhibitor-induced Pneumonitis are under consideration.

Relief expects to “up list” to a major U.S. stock exchange

Throughout 2021 Relief will continue to evaluate and take steps to facilitate interest from institutional investors. In addition, the Company expects to “up list” to a major U.S. stock exchange in the coming months.

Relief’s 2020 Annual Report is available for download at https://relieftherapeutics.com/investor-relations.

What is your IP position for RLF-100™?

Relief holds a patent covering potential formulations of RLF-100™ in the United States valid until at least July 2029, with extension opportunities up to five years as well as in the EU and RoW (Great Britain, Germany, Turkey, Spain, Switzerland, Netherlands, Denmark, Ireland, Austria, PRC and Mexico) valid until at least 2026, excluding extension opportunities comparable to the U.S.

What is the nature of your partnership with NeuroRx?

On September 21, 2020, Relief and NeuroRx announced the completion of their partnership agreement for the commercialization of RLF-100™ worldwide. The two organizations have agreed to share all profits from sales of RLF-100™ for all indications related to COVID-19 and potentially other respiratory indications on a global basis. They have agreed that NeuroRx will lead commercialization in the United States, Canada, and Israel, while Relief will lead commercialization in Europe and the rest of the world. Profits from sales will be allocated to Relief and NeuroRx on a 50/50 basis in the U.S., Canada and Israel, 85/15 (in favor of Relief) in Europe, and 80/20 (in favor of Relief) in all other territories.

How long will it take the FDA to approve RLF-100™ after top-line data are available?

NeuroRx has indicated it anticipates submitting a request for EUA in the population of critically ill patients who are on high flow nasal oxygen who have exhausted all currently approved treatments, should the trends seen in the day 60 data support this.

Assuming that the 60-day data are positive, the FDA could at that time consider granting EUA, which would permit the drug to be launched in Q2 2021. A full New Drug Application (NDA) requesting marketing approval could be submitted at a later time, based on positive top-line results and including full chemistry, manufacturing and controls (CMC) data as well as additional information on the profile of the drug from other previously-conducted clinical and preclinical studies. The FDA granted RLF-100™ Fast Track designation, which, among other things, makes RLF-100™ eligible for Priority Review if relevant criteria are met. Priority Review designation means the FDA’s goal is to take action on an application within six months compared to ten months under standard review. It would be reasonable to expect Priority Review for applications filed under the Coronavirus Treatment Acceleration Program (CTAP). RLF-100™ is part of this program, which was promulgated by the FDA earlier this year in express response to the emergence of the COVID-19 pandemic.

What is the nature of your partnership with Acer Therapeutics?

On March 22, 2021, Relief and Acer announced the signing of a Collaboration and License Agreement for the worldwide development and commercialization of ACER-001. Under the terms of the agreement, Acer will receive approximately $10 million in cash upon signing (originally $14 million, which was offset by cancellation of the $4.0 million outstanding balance of the prior loan from Relief to Acer following the signing of an exclusivity Option Agreement in January 2021 and a small amount of accrued interest). In addition, Relief has agreed to pay up to $20 million in U.S. development and commercial launch costs for the Urea Cycle Disorders (UCDs) and Maple Syrup Urine Disease (MSUD) indications. Acer will retain development and commercialization rights in the U.S., Canada, Brazil, Turkey and Japan. The companies will split net profits from Acer’s territories 60:40 in favor of Relief. In addition, Relief has licensed the rights for the rest of the world, where Acer will receive from Relief a 15% royalty on all net sales and other revenues received in Relief’s territories. Acer may also receive a total of $6 million in development milestone payments following the first European (EU) marketing approvals for UCDs and MSUD.

Softwareone

SOFTWAREONE - SIEHE LINK auf ihrer Homepage Media Release
https://www.softwareone.com/en/press/2021/03/25/application-services-str...

SoftwareONE is training up to 5,000 additional specialists till 2023, strategic agreement and business plan with Microsoft, expected revenue growth over that period.

• SoftwareONE to expand its application services and SAP on Azure capabilities by hiring and training up to 5,000 additional specialists by the end of 2023, in line with the SoftwareONE and Microsoft business plan and expected revenue growth over that period.
• Microsoft to provide SoftwareONE with investment, training, certification and engineering engagement for practice development

SoftwareONE Holding AG, a leading global provider of end-to-end software and cloud technology solutions, announced that is has reached a strategic agreement with Microsoft to accelerate growth for application services and SAP on Microsoft Azure globally, building on their longstanding successful relationship.

Dieter Schlosser, CEO of SoftwareONE, said: “The extended agreement with Microsoft is a testament to the longstanding and successful relationship we built over the last 30 years and will help SoftwareONE to achieve its growth ambitions in the two focus areas of application services and SAP in the cloud. This will ensure we address some of the major needs that our customers will have over the coming years to drive their digital transformation.”

“Our customers are looking for help modernizing legacy applications and their SAP infrastructure. Our cloud services are an incredible asset to help them through this transformation. SoftwareONE, one of our Azure Expert Managed Service Providers, has seen this as an opportunity as well, so it was a natural choice to align our objectives for the benefits of our joint customers. We expect this agreement to help us transform over 3,000 customers worldwide in the next three years”, said Gavriella Schuster, Corporate Vice President, One Commercial Partner at Microsoft.

Strengthening of application modernization services

Applications are a vital support for organizations and their processes. Still, many of these applications have become obsolete, as they no longer respond to the dynamics that customers need, cause high administration and maintenance costs and are slowing down business innovation processes. Modernizing an application can bring companies operational cost savings along with less administration and support burdens. Research analysts expect that 80% of all new applications developed will be deployed on containers by 2024, which increases the need for experts with specific skills and process know-how. The deepened relationship with Microsoft, and the Microsoft Advanced Specialization credential for “Modernizations of Web Applications on Azure” will further equip SoftwareONE to support customers to build and implement their application modernization strategy.

”The collaboration with Microsoft allows SoftwareONE to strengthen its Application Modernization Advisory and managed services team which will significantly expand our capacity for software developers, architects and designer over the next three years. We will bring these expanded capabilities to our global customer base, helping them transform legacy applications from old into cloud-enabled technologies”, Joaquin Potel, the global owner of SoftwareONE’s application services business, commented.

Supporting SAP journey to Azure cloud

In recent years, SoftwareONE has accelerated its SAP cloud competencies both organically and through several strategic acquisitions, brining market-leading technology competency to the global customer base, helping them with their SAP journey to the cloud and S/4HANA adoption. According to industry estimates, SAP’s platform upgrade fuels a market opportunity of an estimated USD 100bn by 2027.

Daniel DaVinci, global owner of SoftwareONE’s SAP services business, said: “In combination with our made-for-cloud SAP services portfolio, this agreement with Microsoft provides us an exceptional opportunity to extend and further develop our SAP on Azure center of excellence, our SAP service accelerators, and managed platform offering worldwide. This enables us to provide our customers a reliable pathway to realizing the benefits of the Azure cloud platform for modern SAP systems”.
João Couto, Vice President for SAP Business Unit at Microsoft, said: ”We see a tremendous market opportunity to support SAP customers in accelerating their transformation journey to the cloud. SoftwareONE is one of our global partners with our SAP on Azure Advanced Specialization, that has shown great speed in ramping up their SAP business practice. We are excited to tackle this opportunity together and help our joint customers.”

SOFTWAREONE - SIEHE LINK auf ihrer Homepage Media Release
https://www.softwareone.com/en…-agreement-with-microsoft

SoftwareONE is training up to 5,000 additional specialists till 2023, strategic agreement and business plan with Microsoft, expected revenue growth over that period.

• SoftwareONE to expand its application services and SAP on Azure capabilities by hiring and training up to 5,000 additional specialists by the end of 2023, in line with the SoftwareONE and Microsoft business plan and expected revenue growth over that period.
• Microsoft to provide SoftwareONE with investment, training, certification and engineering engagement for practice development

SoftwareONE Holding AG, a leading global provider of end-to-end software and cloud technology solutions, announced that is has reached a strategic agreement with Microsoft to accelerate growth for application services and SAP on Microsoft Azure globally, building on their longstanding successful relationship.

Dieter Schlosser, CEO of SoftwareONE, said: “The extended agreement with Microsoft is a testament to the longstanding and successful relationship we built over the last 30 years and will help SoftwareONE to achieve its growth ambitions in the two focus areas of application services and SAP in the cloud. This will ensure we address some of the major needs that our customers will have over the coming years to drive their digital transformation.”

“Our customers are looking for help modernizing legacy applications and their SAP infrastructure. Our cloud services are an incredible asset to help them through this transformation. SoftwareONE, one of our Azure Expert Managed Service Providers, has seen this as an opportunity as well, so it was a natural choice to align our objectives for the benefits of our joint customers. We expect this agreement to help us transform over 3,000 customers worldwide in the next three years”, said Gavriella Schuster, Corporate Vice President, One Commercial Partner at Microsoft.

Strengthening of application modernization services

Applications are a vital support for organizations and their processes. Still, many of these applications have become obsolete, as they no longer respond to the dynamics that customers need, cause high administration and maintenance costs and are slowing down business innovation processes. Modernizing an application can bring companies operational cost savings along with less administration and support burdens. Research analysts expect that 80% of all new applications developed will be deployed on containers by 2024, which increases the need for experts with specific skills and process know-how. The deepened relationship with Microsoft, and the Microsoft Advanced Specialization credential for “Modernizations of Web Applications on Azure” will further equip SoftwareONE to support customers to build and implement their application modernization strategy.

”The collaboration with Microsoft allows SoftwareONE to strengthen its Application Modernization Advisory and managed services team which will significantly expand our capacity for software developers, architects and designer over the next three years. We will bring these expanded capabilities to our global customer base, helping them transform legacy applications from old into cloud-enabled technologies”, Joaquin Potel, the global owner of SoftwareONE’s application services business, commented.

Supporting SAP journey to Azure cloud

In recent years, SoftwareONE has accelerated its SAP cloud competencies both organically and through several strategic acquisitions, brining market-leading technology competency to the global customer base, helping them with their SAP journey to the cloud and S/4HANA adoption. According to industry estimates, SAP’s platform upgrade fuels a market opportunity of an estimated USD 100bn by 2027.

Daniel DaVinci, global owner of SoftwareONE’s SAP services business, said: “In combination with our made-for-cloud SAP services portfolio, this agreement with Microsoft provides us an exceptional opportunity to extend and further develop our SAP on Azure center of excellence, our SAP service accelerators, and managed platform offering worldwide. This enables us to provide our customers a reliable pathway to realizing the benefits of the Azure cloud platform for modern SAP systems”.
João Couto, Vice President for SAP Business Unit at Microsoft, said: ”We see a tremendous market opportunity to support SAP customers in accelerating their transformation journey to the cloud. SoftwareONE is one of our global partners with our SAP on Azure Advanced Specialization, that has shown great speed in ramping up their SAP business practice. We are excited to tackle this opportunity together and help our joint customers.”

In USA kaufen und kaufen sie jetzt Relief Therapeutics..siehe

https://finance.yahoo.com/quote/RLFTF/history?p=RLFTF heutiges Handelsvolumen übersteigt durchschnittliches Handelsvolumen von 13'881'488 Stück in den USA, diese wissen wahrscheinlich mehr als wir, da sie in USA wohnen und Breaking news haben, die wir vielleicht noch nicht wissen?

ich bleibe dabei und warte ab....bitte nicht ständig kaufen und verkaufen, der Kurs wird sonst ständig ausgebremst....:-) Danke . Es gewinnen am Schluss alle, wenn man einfach jetzt abwartet und steigen lässt.... oder dazu kauft, wenn man noch Geld übrig hätte und möchte...

Relief-Beitrag NEUESTES - KAUFEMPFEHLUNG AUS USA 13.08.20

Relief Therapeutics - Aktie kaufen sehr empfehlenswert gemäss unten stehendem englischen Text. Patent existiert, Nachahmer haben es schwer, dieses zu kopieren gemäss untenstehendem Text - Bereit für Partnerschaft mit einem GROSSEN PHARMAKONZERN IN USA für Herstellung und Distribution....

Hier der Link (daras kopiert) : https://finance.yahoo.com/quote/RLFTF/community?p=RLFTF

Jesse 11 hours ago : Some great points made during Dr Jonathan Javitt's interview this morning:

1) Next week, Houston Methodist hospital will provide update on critical ill patients and their outcomes. This is part of the Open Label study being done. He mentioned not to ruin the surprise but out of 5 patients on ECMO (Ventilators and very ill) 4 are alive. Dr Yosef to provide update next week.
2) Mentioned that in Brazil, doctors have already experience the great results on their patients from taking RLF 100
3) There is a new trial ready to start in September in regards to the INHALER form (VIP). They received FDA emergency designation on this.
4) No Safety Concerns on more than 100 patients that have been administered RLF 100. Not a single incident of adverse or safety concern with the drug.
5) Dr. Javitt met with the FDA last week and the outcome was a very positive scientific discussion.
6) Dr. Javitt is very connected and has the respect of the FDA based on his work and experience. He mentioned that his investigation drug application was approved by FDA within 48 hours when it can take weeks or months. He also mentioned that he requested to meet with the FDA. This usually takes up to 60 days to receive a response. He received response from FDA within 1 week.
7) RLF 100 is being administered in Houston, Miami, Kentucky, California. By the end of month should be at more than 10 hospitals.
Ready to announce a partnership with a BIG PHARMA for manufactured and distribution
9) We are about to receive an update by the Data Monitoring Committee on the trial taking place.
10) Provided evidence in X rays as to how the drug has helped critically ill patients go through a rapid recovery.

When the FDA is involved, NIH is involved, Hospitals all over the nation are involved, Physicians are involved, and most important, REAL PEOPLE (ILL PATIENTS) are involved, you clearly know this is a real and serious company making a difference to people's lives and their families. We as investors are here to support the company with our investments and in time we also will get rewarded....which will be very soon!!!.

Remember: YOU SELL ON DIPS, YOU LOSE YOUR MONEY. YOU BUY ON DIPS AND HOLD, YOU WIN. WHEN THERE IS A DIP, I DO NOT WORRY. THE QUESTION IS, DO I STILL OWN MY SHARES? YES, NO NEED TO WORRY JUST HOLD. THIS IS HOW THE STOCK MARKET WORKS. THE KEY IS TO FIND A GOOD COMPANY WITH GREAT POTENTIAL AND AT A GOOD ENTRY PRICE.....WE HAVE FOUND IT!!!!!

Habe nun aufgestockt mit Relief Therapeutics.